Home › Follicular Lymphoma › Tennessee › Nashville
Follicular Lymphoma clinical trials in Nashville, TN
18 studies for Follicular Lymphoma are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RecruitingPhase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingPhase 2/3
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingPhase 3
- Research Site, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
- Research Site, Nashville
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
RecruitingPhase 3
- Tennessee Oncology, Nashville
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RecruitingPhase 3
- Vanderbilt University Medical Center, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Vanderbilt-Ingram Cancer Center, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Vanderbilt University Medical Center, Nashville
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
RecruitingPhase 2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- TriStar BMT, Nashville
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RecruitingPhase 1
- Tennessee Oncology, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Nashville
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Houston, TX18 studies
- Boston, MA17 studies
- Baldwin Park, CA16 studies
- Seattle, WA15 studies
- Durham, NC15 studies
- Columbus, OH13 studies
- Salt Lake City, UT13 studies
- Chicago, IL12 studies
- San Antonio, TX12 studies
- Philadelphia, PA12 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.